



## **THOMPSON CANCER SURVIVAL CENTER TO TAKE CANCER PROGRAM TO THE NEXT LEVEL WITH PURCHASE OF ELEKTA INFINITY TREATMENT SYSTEM**

### **Press Release**

Stockholm, Sweden, September 18, 2008

**Thompson Cancer Survival Center (TCSC, Knoxville, Tennessee) has placed an order for Elekta Infinity, reaffirming their long-term commitment to deliver the most advanced radiation therapy treatments. The addition of Elekta Infinity, a linear accelerator optimized for Volumetric Modulated Arc Therapy (VMAT) will complement the center's decade-long plan to improve patient outcomes.**

Chester Ramsey, Ph.D., director of medical physics at TCSC expects the time savings with Elekta VMAT, a new treatment that targets tumors with high doses of radiation while protecting healthy tissue, to be dramatic. "With fixed-gantry IMRT delivery on other linear accelerators, it currently takes 7 to 15 minutes to treat most of our IMRT patients. We estimate that VMAT treatment delivery times with Elekta Infinity will be reduced by at least 50 percent, without compromising treatment quality."

"At TCSC, clinicians and researchers began using single rotation, constant dose rate volume modulated arc therapy more than 10 years ago," explains Ramsey. "The added capabilities of Elekta Infinity, such as simultaneous control of gantry rotation speed, collimator rotation and variable dose rate will advance our cancer treatment program to a new level."

TCSC currently treats 100-150 patients per day at three locations. Dr. Ramsey expects to treat up to 40 patients each day with Elekta Infinity, about half of which will be VMAT treatments for prostate, head and neck, lung, esophagus and brain cancers.

In addition to Elekta Infinity, TCSC also is scheduled to install an Elekta Synergy<sup>®</sup> linear accelerator. Elekta Synergy is an advanced multi-functional linear accelerator that enables clinicians to image and treat patients simultaneously.

Clinical information from all treatment systems will be streamlined with MOSAIQ<sup>®</sup> image-enabled oncology EMR, already in use at TCSC. MOSAIQ integrates patient information and charts from initial diagnosis and staging through scheduling, planning, treatment and subsequent follow-up, maximizing efficiency and minimizing patient waiting times.

Dr. Ramsey says the new additions at TCSC will provide patients with a higher standard of cancer care than ever before. "The clinicians and researchers at TCSC are extremely excited about our new relationship with Elekta," he adds.

\*\*\*\*\*

**For further information, please contact:**

Media:



Michelle Lee, Elekta, Inc  
Tel: 1- 770-670-2447, e-mail: michelle.lee@elekta.com

Inverstors:  
Lena Schattauer, Investor Relations, Elekta AB  
Tel: +46 8 587 257 22, +46 70 595 51 00, e-mail: lena.schattauer@elekta.com

### **About Elekta**

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAB. For more information about Elekta, please visit [www.elekta.com](http://www.elekta.com).